Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Find generic entry opportunities
Manage your formulary budget
|Title:||7.alpha.-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor|
|Abstract:||Novel 3,20-dioxo-7.alpha.-halogeno-1,4-pregnadienes are described and their use as anti-inflammatory agents. Preferred are 7.alpha.-bromo- and 7.alpha.-chloro- derivatives, particularly 7.alpha.-bromo- and 7.alpha.-chloro-1,4-pregnadienes-11.beta.,17.alpha.,21-triol-3,20-dione 17,21-dihydrocarboncarboxylates, the 16-methyl and 16-methylene derivatives thereof being particularly valuable as topical anti-inflammatory agents.|
|Inventor(s):||Green; Michael J. (Kendall Park, NJ), Shue; Ho-Jane (Belleville, NJ)|
|Assignee:||Schering Corporation (Kenilworth, NJ)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.